Eli Lilly and Company (NYSE:LLY – Free Report) – Equities research analysts at Erste Group Bank upped their FY2026 earnings per share (EPS) estimates for shares of Eli Lilly and Company in a report issued on Tuesday, May 12th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $36.30 per share for the year, up from their prior forecast of $36.06. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $35.80 per share.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS.
Eli Lilly and Company Stock Performance
Eli Lilly and Company stock opened at $1,006.83 on Friday. The stock has a market cap of $948.17 billion, a P/E ratio of 35.77, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a 50 day moving average of $939.86 and a 200-day moving average of $996.95. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.
Institutional Investors Weigh In On Eli Lilly and Company
Hedge funds have recently added to or reduced their stakes in the stock. Maryland Capital Advisors Inc. bought a new stake in Eli Lilly and Company in the fourth quarter valued at $25,000. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at $25,000. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company in the fourth quarter valued at $30,000. Miller Global Investments LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at $33,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.
Eli Lilly and Company Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.
Eli Lilly and Company News Summary
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Guggenheim raised its price target on Lilly by $52 after the company’s Q1 report, reinforcing confidence that earnings momentum and demand for its key drugs remain strong. Analyst Raises Eli Lilly (LLY) Price Target by $52 Following Q1 Report
- Positive Sentiment: Lilly released encouraging late-stage obesity data showing patients maintained significant weight loss after switching to Foundayo or lower-dose Zepbound, supporting the durability of its weight-loss portfolio. Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
- Positive Sentiment: Additional obesity coverage highlighted Lilly’s push into next-generation GLP-1 drugs, including oral pills and retatrutide, which could help defend its market leadership against competitors like Novo Nordisk. Eli Lilly Obesity Data Support Oral Shift And Undervalued Growth Story
- Positive Sentiment: Market commentary remains bullish, with articles citing Lilly’s “bull market” setup and the possibility of the stock moving toward $1,100 after a very strong quarter. Jim Cramer Sees a ‘Bull Market’ for Eli Lilly Stock (LLY)
- Positive Sentiment: Lilly also expanded its pipeline with new clinical trials in ALS, GI disorders, and vitiligo, adding longer-term optionality beyond its current blockbuster products. Lilly Extends ALS Pipeline With New Long-Term Safety Trial for LY4256984
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
